Main results of the ADVANCE study: clinical interpretation for endocrinologists
https://doi.org/10.14341/2072-0351-5391
Abstract
Результаты ADVANCE приобретают особое значение. Могло показаться, что плохие новости исследования ACCORD могут поколебать уверенность специалистов в важности и необходимости достижения хорошего гликемического контроля при СД. Благодаря результатам исследования ADVANCE получены четкие доказательства того, что стратегия постепенного усиления сахароснижающей терапии с целью достижения целевого уровня гликированного гемоглобина (6,5%) безопасна и эффективна в отношении снижения риска поражения почек и макрососудистых исходов.
About the Authors
Alsu Gafurovna Zalevskya
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
A Yu Babenko
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
A R Volkova
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
References
1. International Diabetes Federation. // Diabetes Atlas 3-rd Ed.Brussels: International Diabetes Federation, 2006.
2. Anselmino M. et al. // Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected Diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. // Eur. Heart J., 2007, Dec 21: 18156611.
3. Gaede P et al. // Effect of multifactorial intervention on mortality in type 2 diabetes. // N.Engl. J.Med; 2008: 358: 580-591.
4. The Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. // The Seventh Report of the Joint National Committee: JNCVII Express. // JAMA, 2003: 289 (19) 2560:2572
5. DCCT Research Group: The effect of intensive diabetes management on macrovascular events and risk factors in the DCCT. // Am.J.Cardiol. 1995; 75: 894-903.
6. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet, 1998; 352: 837-853.
7. Mancia G.et al. // Systolic and diastolic blood pressure control in antihypertensive drug trials // J.Hypertens., 2002; 20: 1461-1464.
8. Dahlof B. et al. // For the ASCOT investigators. Prevention of Cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. // Lancet 2005, 366:895-906.
9. ADVANCE Collaborative Group. // Intensive Blood Glucose Control and vascular outcomes in patients with type 2 diabetes // N.Engl. J Med. 2008; 358: 2560-2572.
10. The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 Diabetes; // N.Engl. J.Med. 2008; 358: 2545-2559.
11. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes; // N.Engl. J.Med. 2009, 360, l-ll.
12. Zammitt N. N. et al. // Hypoglycemia in type 2 Diabetes. // Diabetes Care 2005; 28: 2948-2961.
13. Miller C. D. et al. // Hypoglycemia in patients with type 2 diabetes mellitus. // Arch. Int. Med. 2005; 161: 1653-1659.
14. ADVANCE Collaborative Group. // Rationale and design of the ADVANCE Study: a Randomized trial of blood pressure lowering and intensive glucose control in high risk individuals with type 2 Diabetes mellitus. // J. Hypertens. 2001; 19, suppl. 4: S21-S28.
Review
For citations:
Zalevskya A.G., Babenko A.Yu., Volkova A.R. Main results of the ADVANCE study: clinical interpretation for endocrinologists. Diabetes mellitus. 2009;12(2):14-17. (In Russ.) https://doi.org/10.14341/2072-0351-5391
Views:
781
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
